Back to Journals » Clinical Interventions in Aging » Volume 9

Efficacy and safety of febuxostat in elderly female patients

Authors Mizuno T, Hayashi T, Hikosaka S, Shimabukuro Y, Murase M, Takahashi K, Hayashi H, Yuzawa Y, Nagamatsu T, Yamada S

Received 9 July 2014

Accepted for publication 31 July 2014

Published 4 September 2014 Volume 2014:9 Pages 1489—1493

DOI https://doi.org/10.2147/CIA.S70855

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Richard Walker

Tomohiro Mizuno,1,2 Takahiro Hayashi,3 Sayo Hikosaka,1 Yuka Shimabukuro,1 Maho Murase,1 Kazuo Takahashi,2 Hiroki Hayashi,2 Yukio Yuzawa,2 Tadashi Nagamatsu,1 Shigeki Yamada3

1Department of Analytical Pharmacology, Graduate School of Pharmacy, Meijo University, Nagoya, Japan; 2Department of Nephrology, School of Medicine, Fujita Health University, Toyoake, Japan; 3Department of Clinical Pharmacy, School of Medicine, Fujita Health University, Toyoake, Japan

Background: Maintenance of low serum urate levels is important for the management of gout. Achieving the recommended serum urate levels of less than 6.0 mg/dL is difficult in elderly (65 years of age or older) patients with renal impairment. Xanthine oxidase inhibitors allopurinol and febuxostat are used for this purpose. Although febuxostat had been shown to be efficacious in elderly patients, its safety and efficacy in elderly female patients with hyper­uricemia remain unclear.
Objective: The aim of this study was to assess the efficacy and safety of febuxostat in elderly female patients.
Methods: We studied a retrospective cohort study. The study included elderly Japanese patients (65 years of age or older) who were treated with febuxostat at Fujita Health University Hospital from January 2012 to December 2013. The treatment goal was defined as achievement of serum urate levels of 6.0 mg/dL or lower within 16 weeks; this was the primary endpoint in the present study. Adverse events of febuxostat were defined as more than twofold increases in Common Terminology Criteria for adverse events scores from baseline.
Results: We evaluated 82 patients treated with febuxostat during the observation period and classified them into male (n=53) and female (n=29) groups. The mean time to achievement of the treatment goal was significantly shorter in the female group (53 days) than in the male group (71 days). There were no significant differences in adverse events between the 2 groups.
Conclusion: Our findings suggest that the efficacy of febuxostat in elderly female patients is superior to that in elderly male patients and that the safety is equivalent.

Keywords: febuxostat, elderly female patients, hyperuricemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury [Corrigendum]

Mizuno T, Sato W, Ishikawa K, Terao Y, Takahashi K, Noda Y, Yuzawa Y, Nagamatsu T

OncoTargets and Therapy 2017, 10:1001-1002

Published Date: 21 February 2017

Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury

Mizuno T, Sato W, Ishikawa K, Terao Y, Takahashi K, Noda Y, Yuzawa Y, Nagamatsu T

OncoTargets and Therapy 2015, 8:1701-1706

Published Date: 10 July 2015

Use of pharmacist blood pressure telemonitoring systems in diagnosis of nocturnal hypertension in a young healthy male

Mizuno T, Matsumoto C, Nabetani N, Yasuda Y, Nagamatsu T, Umemura N

Patient Preference and Adherence 2014, 8:1169-1171

Published Date: 1 September 2014

Risk factors for an early dialysis start in patients with diabetic nephropathy end-stage renal disease

Mizuno T, Hayashi T, Kato R, Noguchi A, Hayashi H, Yuzawa Y, Yamada S, Nagamatsu T

Therapeutics and Clinical Risk Management 2014, 10:73-76

Published Date: 30 January 2014

The influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia

Mizuno T, Mizokami F, Fukami K, Ito K, Shibasaki M, Nagamatsu T, Furuta K

Clinical Interventions in Aging 2013, 8:1323-1328

Published Date: 30 September 2013

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010